BRCC3 antibody - 100 µg
Host : Rabbit
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: BRCA1
BRCA2-containing complex, subunit 3
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 65-70 kDa
Uniprot: P46736
Gene id: 79184
Background: Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains(PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks(DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks(DSBs)(PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates(PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex(CSN), via the interaction of the BRISC complex with the CSN complex(PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1(PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression(PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide(LPS) via its role in IFNAR1 deubiquitination(PubMed:24075985).
Field of research: Signal Transduction, Cancer
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC
Dilution: WB: 1:500-1:2000; IHC: 1:20-1:200
Target: BRCC3
Purification: Immunogen affinity purified
Reactivity: Human, Mouse, Rat, Monkey
![]()
Clonality: Polyclonal
Clone:
Isotype: IgG
Immunogen: BRCA1
BRCA2-containing complex, subunit 3
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 65-70 kDa
Uniprot: P46736
Gene id: 79184
Background: Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains(PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains. Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks(DSBs). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks(DSBs)(PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates(PubMed:20656690, PubMed:24075985, PubMed:26344097, PubMed:26195665). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex(CSN), via the interaction of the BRISC complex with the CSN complex(PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1(PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression(PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide(LPS) via its role in IFNAR1 deubiquitination(PubMed:24075985).
Field of research: Signal Transduction, Cancer
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC
Dilution: WB: 1:500-1:2000; IHC: 1:20-1:200
Target: BRCC3
Purification: Immunogen affinity purified
Reactivity: Human, Mouse, Rat, Monkey